CORPORATE PRESENTATION
AUGUST 2022
Disclaimer
We caution you that this presentation contains forward-looking statements of HilleVax, Inc. ("HilleVax," "we," "us" or similar terms). All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our planned and potential clinical trials and preclinical studies for HIL-214 and any future vaccine candidates, the timing and likelihood of regulatory filings and approvals for HIL-214 and any future vaccine candidates, our ability to commercialize our vaccine candidates, if approved, the impact of COVID-19 on our business, the pricing and reimbursement of our vaccine candidates, if approved, the potential to develop future vaccine candidates, the potential benefits of strategic collaborations and our intent to enter into any strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated product development efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Actual results may differ from those set forth in this presentation due to the risks and uncertainties inherent in our business, including, without limitation: we currently depend entirely on the success of HIL-214, our only vaccine candidate, and we have not yet completed any clinical trials of HIL-214; potential delays in the commencement, enrollment, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research and clinical and preclinical testing; unexpected adverse side effects or inadequate immunogenicity or efficacy of HIL-214 or any future vaccine candidates that may limit their development, regulatory approval, and/or commercialization; unfavorable results from clinical trials; results from prior clinical trials and studies not necessarily being predictive of future results; our ability to maintain undisrupted business operations due to the COVID-19 pandemic, including delaying or disrupting our clinical trials, manufacturing and supply chain; regulatory developments in the United States and foreign countries; our reliance on intellectual property rights under our license agreement with Takeda Vaccines, Inc.; our ability to obtain, maintain and enforce intellectual property protection for our vaccine candidates; we may use our capital resources sooner than we expect; and other risks described in our filings with the SEC, including under the heading "Risk Factors" in the prospectus we filed with the SEC on April 29, 2022 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this presentation, and except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.
2
Significant unmet medical need. Norovirus causes 700M illnesses and 200k deaths worldwide each year1
Clinical PoC demonstrated. Phase 2b field efficacy trial demonstrated clinical proof of concept in adults
Excellent safety profile. Well-tolerated in clinical trials of over >4,500 subjects
Large commercial opportunity. Potential multi-billiondollar commercial opportunity
Seasoned leadership team. World-classvaccine experience
1. Bartsch et al., 2016 | 3 |
Senior Leadership
Rob Hershberg, MD, PhD
CEO & Chair
EVP BD & CSO, Celgene
CEO, VentiRx
CMO, Dendreon
Aditya Kohli, PhD
COO
CBO, Phathom Pharma
VP BD, Scout Bio
Engagement Manager, McKinsey
David Socks
CFO & CBO
CEO & CFO, Phathom Pharma
COO, Incline Therapeutics
SVP, Cadence Pharmaceuticals
Astrid Borkowski, MD, PhD
Chief Medical Officer
Takeda Vaccines, Novartis Vaccines
Kaia Agarwal
SVP Regulatory Affairs
Novartis Vaccines, Genzyme
Steve Lamola, MD
VP Clinical Development
PATH, Gilead
David Swerdlow, MD
VP Medical Affairs
Pfizer Vaccines, CDC
Shannon Harris, PhD
VP Clinical Assays
Seqirus, Pfizer Vaccines
Wendy Talbott
VP Clinical Operations
Novavax, Takeda Vaccines
Anju Chatterji, PhD
SVP Technical Operations
Catalyst, Exelixis, Novartis Vaccines
Tara Raab
VP Quality
Atara, Seqirus, Novartis Vaccines
Paul Bavier, JD
GC and CAO
Velos, Avedro
Shane Maltbie, CPA
VP Finance
TScan, Axcella
Lynn Ferrucci
VP Human Resources
Ziopharm, Clinical Data
4
Board of Directors
Shelley Chu, MD, PhD
Partner, Lightspeed
Gary Dubin, MD
President, Global Vaccine Business Unit, Takeda
Julie Gerberding, MD, MPH
President, Merck Vaccines
Director, CDC
Patrick Heron
Managing General Partner, Frazier
Rob Hershberg, MD, PhD, Chair
Co-founder & CEO, HilleVax
EVP BD & CSO, Celgene
Jeri Hilleman
Audit chair/CFO of multiple public life sciences companies
Aditya Kohli, PhD
Co-founder & COO, HilleVax
Jaime Sepulveda, MD, PhD, MPH
Exec Dir, UCSF Institute for Global Health Sciences
Director, NIH Mexico
Susan Silbermann
President, Pfizer Vaccines
President, Pfizer Emerging Markets
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Hillevax Inc. published this content on 22 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 August 2022 15:45:03 UTC.